Clarus raises $660M for new life sciences fund

Clarus Ventures has raised $660 million for its second life sciences fund. Principals with the fund say they've invested 90 percent of the first biotech fund of $500 million, which was raised in 2005. And the life sciences field has remained hot for investors. The National Venture Capital Association, PricewaterhouseCoopers and Thomson Financial concluded that a third of all venture money went to biotech and medical device makers in the last quarter of 2007. 

"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with...breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation."

- read the release for more
- check out the report from The Boston Globe

Related Articles:
Clarus closes $500M fund. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
The top 20 VC deals of 2007. Report
Biotech, emerging markets are big VC targets. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.